AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Momentus Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Masimo Corp, identified as a 10% beneficial owner of Neuraxis, Inc. (NRXS), filed a Form 4 disclosing a complete exit from its common-stock position on 1 July 2025.

  • Common-stock sales: 531,548 shares sold at $2.25 per share (Code S); beneficial ownership after this trade: 0 shares.
  • Pre-funded warrant conversion: 289,779 shares acquired via automatic warrant exercise at $0.0001 per share (Code C), immediately followed by the sale of the same 289,779 shares at $2.25 per share (Code S).
  • Derivative position: The pre-funded warrant (exercise price $0.0005) was fully exercised/converted (Code M) and now shows 0 derivative securities outstanding.

Net result: Masimo liquidated a total of 821,327 shares, reducing both its direct and derivative holdings in NRXS to zero. Because Masimo previously qualified as an “insider� under Section 16 (10% owner), the disposal is considered material. The filing does not give reasons for the divestiture nor mention any concurrent corporate events at Neuraxis.

Masimo Corp, identificata come proprietaria beneficiaria del 10% di Neuraxis, Inc. (NRXS), ha presentato un Modulo 4 comunicando l'uscita completa dalla sua posizione in azioni ordinarie il 1° luglio 2025.

  • Vendite di azioni ordinarie: 531.548 azioni vendute a 2,25$ per azione (Codice S); proprietà beneficiaria dopo questa operazione: 0 azioni.
  • Conversione di warrant prefinanziati: 289.779 azioni acquisite tramite esercizio automatico del warrant a 0,0001$ per azione (Codice C), seguite immediatamente dalla vendita delle stesse 289.779 azioni a 2,25$ per azione (Codice S).
  • Posizione derivata: Il warrant prefinanziato (prezzo di esercizio 0,0005$) è stato completamente esercitato/convertito (Codice M) e ora non risultano più titoli derivati in essere.

Risultato netto: Masimo ha liquidato un totale di 821.327 azioni, riducendo a zero sia le sue partecipazioni dirette che quelle derivati in NRXS. Poiché Masimo era precedentemente qualificata come “insider� ai sensi della Sezione 16 (proprietario del 10%), la cessione è considerata rilevante. La comunicazione non fornisce motivazioni per la dismissione né menziona eventi societari concomitanti in Neuraxis.

Masimo Corp, identificada como propietaria beneficiaria del 10% de Neuraxis, Inc. (NRXS), presentó un Formulario 4 revelando la salida completa de su posición en acciones ordinarias el 1 de julio de 2025.

  • Ventas de acciones ordinarias: 531,548 acciones vendidas a $2.25 por acción (Código S); propiedad beneficiaria después de esta operación: 0 acciones.
  • Conversión de warrants prefinanciados: 289,779 acciones adquiridas mediante el ejercicio automático de warrants a $0.0001 por acción (Código C), seguidas inmediatamente por la venta de las mismas 289,779 acciones a $2.25 por acción (Código S).
  • Posición derivada: El warrant prefinanciado (precio de ejercicio $0.0005) fue completamente ejercido/convertido (Código M) y ahora no quedan valores derivados en circulación.

Resultado neto: Masimo liquidó un total de 821,327 acciones, reduciendo a cero tanto sus tenencias directas como derivadas en NRXS. Debido a que Masimo previamente calificaba como “insider� bajo la Sección 16 (propietario del 10%), la disposición se considera material. La presentación no proporciona razones para la desinversión ni menciona eventos corporativos concurrentes en Neuraxis.

Masimo CorpëŠ� Neuraxis, Inc. (NRXS)ì� 10% 실질 소유ì£�ë¡� 확ì¸ë˜ì—ˆìœ¼ë©°, 2025ë…� 7ì›� 1ì�ì—� 보통ì£� í¬ì§€ì…˜ì„ ì „ì•¡ ì²­ì‚°í–ˆìŒì� 알리ëŠ� Form 4ë¥� 제출했습니다.

  • 보통ì£� 매ê°: 주당 $2.25ì—� 531,548ì£� 매ë„(코드 S); ì� 거래 í›� 실질 소유ì£� ì§€ë¶�: 0ì£�.
  • ì„ ë‚© 워런íŠ� 전환: 주당 $0.0001ì—� ìžë™ 워런íŠ� 행사ë¡� 289,779ì£� ì·¨ë“(코드 C), 즉시 ê°™ì€ 289,779주를 주당 $2.25ì—� 매ë„(코드 S).
  • 파ìƒìƒí’ˆ í¬ì§€ì…�: ì„ ë‚© 워런íŠ�(행사가ê²� $0.0005)ê°€ 완전íž� 행사/전환ë�(코드 M), 현재 미결 파ìƒì¦ê¶Œì€ 0입니ë‹�.

ìˆ� ê²°ê³¼: MasimoëŠ� ì´� 821,327주를 청산하여 NRXSì—� 대í•� ì§ì ‘ ë°� íŒŒìƒ ë³´ìœ ë¥� ëª¨ë‘ 0으로 줄였습니ë‹�. MasimoëŠ� ì´ì „ì—� 섹션 16(10% 소유ì£�) 하ì—ì„� “내부ìžâ€ë¡œ 분류ë˜ì—ˆê¸°ì—, ì´ë²ˆ ì²˜ë¶„ì€ ì¤‘ëŒ€í•� 사항으로 간주ë©ë‹ˆë‹�. 제출서ì—ëŠ� ë§¤ê° ì‚¬ìœ ë‚� Neuraxisì� ë™ì‹œ 기업 ì´ë²¤íŠ¸ì— ëŒ€í•� 언급ì� 없습니다.

Masimo Corp, identifié comme un détenteur effectif de 10% de Neuraxis, Inc. (NRXS), a déposé un formulaire 4 révélant une sortie complète de sa position en actions ordinaires le 1er juillet 2025.

  • Ventes d'actions ordinaires : 531 548 actions vendues à 2,25 $ par action (Code S) ; détention effective après cette transaction : 0 actions.
  • Conversion de bons de souscription préfinancés : 289 779 actions acquises via l'exercice automatique des bons à 0,0001 $ par action (Code C), immédiatement suivies par la vente des mêmes 289 779 actions à 2,25 $ par action (Code S).
  • Position dérivée : Le bon de souscription préfinancé (prix d'exercice 0,0005 $) a été entièrement exercé/converti (Code M) et ne présente désormais plus aucun titre dérivé en circulation.

Résultat net : Masimo a liquidé un total de 821 327 actions, réduisant ainsi à zéro ses participations directes et dérivées dans NRXS. Étant donné que Masimo était auparavant qualifiée d’� initié » selon la Section 16 (détenteur de 10 %), cette cession est considérée comme significative. Le dépôt ne fournit aucune raison pour cette cession ni ne mentionne d’événements corporatifs concomitants chez Neuraxis.

Masimo Corp, als 10% wirtschaftlicher Eigentümer von Neuraxis, Inc. (NRXS) identifiziert, reichte ein Formular 4 ein, das den vollständigen Ausstieg aus seiner Position in Stammaktien am 1. Juli 2025 offenlegt.

  • Verkauf von Stammaktien: 531.548 Aktien zu je 2,25 $ verkauft (Code S); wirtschaftliches Eigentum nach diesem Handel: 0 Aktien.
  • Umwandlung von vorfinanzierten Warrants: 289.779 Aktien durch automatische Ausübung des Warrants zu je 0,0001 $ erworben (Code C), unmittelbar gefolgt vom Verkauf derselben 289.779 Aktien zu je 2,25 $ (Code S).
  • Derivative Position: Das vorfinanzierte Warrant (Ausübungspreis 0,0005 $) wurde vollständig ausgeübt/umgewandelt (Code M) und weist nun 0 ausstehende derivative Wertpapiere auf.

Nettoergebnis: Masimo hat insgesamt 821.327 Aktien liquidiert und damit sowohl seine direkten als auch derivativen Bestände an NRXS auf null reduziert. Da Masimo zuvor als „Insider� gemäß Abschnitt 16 (10%-Eigentümer) galt, wird die Veräußerung als wesentlich eingestuft. Die Meldung gibt keine Gründe für die Veräußerung an und erwähnt keine gleichzeitigen Unternehmensereignisse bei Neuraxis.

Positive
  • None.
Negative
  • Complete divestiture by 10% owner: Masimo sold 821,327 NRXS shares, eliminating its stake and potentially signaling reduced confidence.
  • Loss of strategic alignment: Departure of a major medical-device shareholder may lessen industry support and governance stability.

Insights

TL;DR: 10% owner Masimo sold 100% of its NRXS stake (821k shares) at $2.25, signaling potential insider pessimism.

The Form 4 is impactful because a single holder representing at least 10% ownership has exited completely. Such wholesale sales often raise questions about future prospects or valuation. The $2.25 sale price sets an observable reference point for near-term trading and removes an overhang of warrants and stock. However, the filing contains no performance metrics or corporate context, so investors should avoid over-extrapolating motives. Taken at face value, insider supply pressure is gone, but the loss of a strategic shareholder like Masimo may reduce perceived sponsorship.

TL;DR: Strategic shareholder exit alters governance dynamics; watch ownership concentration and voting control.

Masimo’s departure eliminates a large, potentially stabilizing block holder. This shifts NRXS’s ownership landscape, possibly increasing influence of remaining insiders or public float volatility. The warrant exercise and immediate sale clarify capital-structure cleanup—no residual cheap securities remain. Nevertheless, sudden disengagement by an aligned medical-technology peer could be viewed negatively by governance-focused investors who value long-term strategic backing.

Masimo Corp, identificata come proprietaria beneficiaria del 10% di Neuraxis, Inc. (NRXS), ha presentato un Modulo 4 comunicando l'uscita completa dalla sua posizione in azioni ordinarie il 1° luglio 2025.

  • Vendite di azioni ordinarie: 531.548 azioni vendute a 2,25$ per azione (Codice S); proprietà beneficiaria dopo questa operazione: 0 azioni.
  • Conversione di warrant prefinanziati: 289.779 azioni acquisite tramite esercizio automatico del warrant a 0,0001$ per azione (Codice C), seguite immediatamente dalla vendita delle stesse 289.779 azioni a 2,25$ per azione (Codice S).
  • Posizione derivata: Il warrant prefinanziato (prezzo di esercizio 0,0005$) è stato completamente esercitato/convertito (Codice M) e ora non risultano più titoli derivati in essere.

Risultato netto: Masimo ha liquidato un totale di 821.327 azioni, riducendo a zero sia le sue partecipazioni dirette che quelle derivati in NRXS. Poiché Masimo era precedentemente qualificata come “insider� ai sensi della Sezione 16 (proprietario del 10%), la cessione è considerata rilevante. La comunicazione non fornisce motivazioni per la dismissione né menziona eventi societari concomitanti in Neuraxis.

Masimo Corp, identificada como propietaria beneficiaria del 10% de Neuraxis, Inc. (NRXS), presentó un Formulario 4 revelando la salida completa de su posición en acciones ordinarias el 1 de julio de 2025.

  • Ventas de acciones ordinarias: 531,548 acciones vendidas a $2.25 por acción (Código S); propiedad beneficiaria después de esta operación: 0 acciones.
  • Conversión de warrants prefinanciados: 289,779 acciones adquiridas mediante el ejercicio automático de warrants a $0.0001 por acción (Código C), seguidas inmediatamente por la venta de las mismas 289,779 acciones a $2.25 por acción (Código S).
  • Posición derivada: El warrant prefinanciado (precio de ejercicio $0.0005) fue completamente ejercido/convertido (Código M) y ahora no quedan valores derivados en circulación.

Resultado neto: Masimo liquidó un total de 821,327 acciones, reduciendo a cero tanto sus tenencias directas como derivadas en NRXS. Debido a que Masimo previamente calificaba como “insider� bajo la Sección 16 (propietario del 10%), la disposición se considera material. La presentación no proporciona razones para la desinversión ni menciona eventos corporativos concurrentes en Neuraxis.

Masimo CorpëŠ� Neuraxis, Inc. (NRXS)ì� 10% 실질 소유ì£�ë¡� 확ì¸ë˜ì—ˆìœ¼ë©°, 2025ë…� 7ì›� 1ì�ì—� 보통ì£� í¬ì§€ì…˜ì„ ì „ì•¡ ì²­ì‚°í–ˆìŒì� 알리ëŠ� Form 4ë¥� 제출했습니다.

  • 보통ì£� 매ê°: 주당 $2.25ì—� 531,548ì£� 매ë„(코드 S); ì� 거래 í›� 실질 소유ì£� ì§€ë¶�: 0ì£�.
  • ì„ ë‚© 워런íŠ� 전환: 주당 $0.0001ì—� ìžë™ 워런íŠ� 행사ë¡� 289,779ì£� ì·¨ë“(코드 C), 즉시 ê°™ì€ 289,779주를 주당 $2.25ì—� 매ë„(코드 S).
  • 파ìƒìƒí’ˆ í¬ì§€ì…�: ì„ ë‚© 워런íŠ�(행사가ê²� $0.0005)ê°€ 완전íž� 행사/전환ë�(코드 M), 현재 미결 파ìƒì¦ê¶Œì€ 0입니ë‹�.

ìˆ� ê²°ê³¼: MasimoëŠ� ì´� 821,327주를 청산하여 NRXSì—� 대í•� ì§ì ‘ ë°� íŒŒìƒ ë³´ìœ ë¥� ëª¨ë‘ 0으로 줄였습니ë‹�. MasimoëŠ� ì´ì „ì—� 섹션 16(10% 소유ì£�) 하ì—ì„� “내부ìžâ€ë¡œ 분류ë˜ì—ˆê¸°ì—, ì´ë²ˆ ì²˜ë¶„ì€ ì¤‘ëŒ€í•� 사항으로 간주ë©ë‹ˆë‹�. 제출서ì—ëŠ� ë§¤ê° ì‚¬ìœ ë‚� Neuraxisì� ë™ì‹œ 기업 ì´ë²¤íŠ¸ì— ëŒ€í•� 언급ì� 없습니다.

Masimo Corp, identifié comme un détenteur effectif de 10% de Neuraxis, Inc. (NRXS), a déposé un formulaire 4 révélant une sortie complète de sa position en actions ordinaires le 1er juillet 2025.

  • Ventes d'actions ordinaires : 531 548 actions vendues à 2,25 $ par action (Code S) ; détention effective après cette transaction : 0 actions.
  • Conversion de bons de souscription préfinancés : 289 779 actions acquises via l'exercice automatique des bons à 0,0001 $ par action (Code C), immédiatement suivies par la vente des mêmes 289 779 actions à 2,25 $ par action (Code S).
  • Position dérivée : Le bon de souscription préfinancé (prix d'exercice 0,0005 $) a été entièrement exercé/converti (Code M) et ne présente désormais plus aucun titre dérivé en circulation.

Résultat net : Masimo a liquidé un total de 821 327 actions, réduisant ainsi à zéro ses participations directes et dérivées dans NRXS. Étant donné que Masimo était auparavant qualifiée d’� initié » selon la Section 16 (détenteur de 10 %), cette cession est considérée comme significative. Le dépôt ne fournit aucune raison pour cette cession ni ne mentionne d’événements corporatifs concomitants chez Neuraxis.

Masimo Corp, als 10% wirtschaftlicher Eigentümer von Neuraxis, Inc. (NRXS) identifiziert, reichte ein Formular 4 ein, das den vollständigen Ausstieg aus seiner Position in Stammaktien am 1. Juli 2025 offenlegt.

  • Verkauf von Stammaktien: 531.548 Aktien zu je 2,25 $ verkauft (Code S); wirtschaftliches Eigentum nach diesem Handel: 0 Aktien.
  • Umwandlung von vorfinanzierten Warrants: 289.779 Aktien durch automatische Ausübung des Warrants zu je 0,0001 $ erworben (Code C), unmittelbar gefolgt vom Verkauf derselben 289.779 Aktien zu je 2,25 $ (Code S).
  • Derivative Position: Das vorfinanzierte Warrant (Ausübungspreis 0,0005 $) wurde vollständig ausgeübt/umgewandelt (Code M) und weist nun 0 ausstehende derivative Wertpapiere auf.

Nettoergebnis: Masimo hat insgesamt 821.327 Aktien liquidiert und damit sowohl seine direkten als auch derivativen Bestände an NRXS auf null reduziert. Da Masimo zuvor als „Insider� gemäß Abschnitt 16 (10%-Eigentümer) galt, wird die Veräußerung als wesentlich eingestuft. Die Meldung gibt keine Gründe für die Veräußerung an und erwähnt keine gleichzeitigen Unternehmensereignisse bei Neuraxis.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kabot Brian

(Last) (First) (Middle)
C/O MOMENTUS INC.
3901 N. FIRST STREET

(Street)
SAN JOSE CA 95134

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Momentus Inc. [ MNTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/30/2025 A 16,294 A $0 22,698 D
Class A Common Stock 28,750 I By SRC-NI Holdings LLC(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 06/30/2025 A 16,294 (3) (3) Class A Common Stock 16,294 $0 16,294 D
Explanation of Responses:
1. Brian Kabot, Juan Manuel Quiroga and Edward Freedman are the managers of SRC-NI Holdings LLC ("SRC-NI") and have voting and investment discretion with respect to the securities held by SRC-NI. As such, each of them may be deemed to share beneficial ownership of the securities held directly by SRC-NI. The Reporting Person disclaims any beneficial ownership of the reported securities other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Momentus, Inc. Class A Common Stock.
3. The RSUs will vest in full on the earlier to occur of June 30, 2026 or the day before the 2026 Annual Meeting, subject to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
Remarks:
/s/ John Rood, Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Momentus Inc

NASDAQ:MNTS

MNTS Rankings

MNTS Latest News

MNTS Latest SEC Filings

MNTS Stock Data

9.81M
5.42M
3.64%
8.31%
7.88%
Aerospace & Defense
Guided Missiles & Space Vehicles & Parts
United States
SAN JOSE